2022-08-30 | NYSE:VEEV | Press release

Global medtech CRO gains agility to build studies in-house and accelerate in-study changes

PLEASANTON, Calif., August 30, 2022 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Veranex is using Veeva Vault CDMS to accelerate study construction and simplify clinical data management. Global Contract Research Organization (CRO) can use Vault CDMS for electronic data capture (EDC), data coding and cleaning. Vault CDMS enables their study teams to quickly create complex studies, migrate trials from other solutions, and make mid-study changes without any downtime.

“Veeva’s innovative technology and industry expertise make it the perfect partner to help us meet the demands of highly complex studies,” said Richard Murg, Senior Vice-President, Business Development at Veranex. “Veeva Vault CDMS provides advanced features that are easy to use, dramatically streamlining our database builds and improving collaboration with customers.”

Veranex serves the medical technology industry by providing design, engineering, regulatory, preclinical research, clinical development, commercial strategy and market access services. By modernizing clinical data management with Vault CDMS, Veranex has a scalable system that can accelerate the development and execution of high-quality trials.

“Bringing together Veranex’s experience to tackle the toughest data management challenges with the flexibility of Veeva Vault CDMS is a recipe for effective clinical studies,” said Manny Vazquez, director of clinical strategy for Veeva Vault. “We are pleased to support their efforts to transform clinical data management into seamless processes that can accelerate the development of new medical products.”

Veranex is a member of the Vault CDMS Partner Program. For CROs interested in learning more about the program, contact [email protected]

Vault CDMS is part of Veeva Vault Clinical Suite, the industry’s first cloud platform that unifies clinical data management and operations. Learn why more companies are using Vault CDMS to streamline data collection, aggregation, and cleansing at the Veeva R&D and Quality Summit. Professionals in the life sciences industry can register for the October 19-20 in-person event in Boston.

Further information

To learn more about Veeva Vault CDMS, visit: veeva.com/VaultCDMS Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veevasystems on Twitter: twitter.com/veevasystems

About Veranex

Veranex is the only truly comprehensive, global, technology-based service provider dedicated to the medical technology industry. Offering expert advice for each of its four pillars from conception to commercialization – engineering and design, clinical, market access and regulatory – Veranex enables accelerated time to market, controlled development costs, risk mitigation development and an accelerated assessment of market viability. At every step, Veranex customers save time and money, while its comprehensive solutions unify the entire development process. Follow Veranex on LinkedIn.

About Veeva systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a public benefit company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva forward-looking statements

This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits of using our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this press release and we undertake no obligation to update these statements. There are numerous risks that could adversely impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2022which you can find here (a summary of the risks that could impact our business can be found on pages 37 and 38), and in our subsequent filings with the SEC, which you can access at sec.gov.

Quote See original content to download multimedia: https://www.prnewswire.com/news-releases/veranex-accelerating-clinical-trials-with-veeva-vault-cdms-301614137.html

SOURCE Veeva Systems

Comments are closed.